MR Imaging of Hepatocellular Adenomas and Differential Diagnosis Dilemma
- PMID: 23606972
- PMCID: PMC3623472
- DOI: 10.1155/2013/374170
MR Imaging of Hepatocellular Adenomas and Differential Diagnosis Dilemma
Abstract
HEPATOCELLULAR ADENOMAS (HCAS) ARE CURRENTLY CATEGORIZED INTO DISTINCT GENETIC AND PATHOLOGIC SUBTYPES AS FOLLOWS: inflammatory hepatocellular adenoma, hepatocyte-nuclear-factor-1-alpha (HNF-1 α -mutated) hepatocellular adenoma, and β -catenin-mutated hepatocellular adenomas; the fourth, defined as unclassified subtype, encompasses HCAs without any genetic abnormalities. This classification has accepted management implications due to different risks of haemorrhage and malignant transformation of the four subtypes. Imaging guided biopsy and/or surgical resection very important in obtaining definitive characterization; nevertheless, MRI with intra-extravascular and hepatobiliary (dual phase) agents, is an important tool not only in differential subtypes definition but even in surveillance with early identification of complications and discovery of some signs of HCA malignant degeneration. Inflammation, abnormal rich vascularisation, peliotic areas, and abundant fatty infiltration are pathologic findings differently present in the HCA subtypes and they may be detected by multiparametric MRI approach. Lesion enlargement and heterogeneity of signal intensity and of contrast enhancement are signs to be considered in malignant transformation. The purpose of this paper is to present the state of the art of MRI in the diagnosis of HCA and subtype characterization, with particular regard to morphologic and functional information available with dual phase contrast agents, and to discuss differential diagnosis with the most common benign and malignant lesions mimicking HCAs.
Figures













Similar articles
-
Qualitative and Quantitative Gadoxetic Acid-enhanced MR Imaging Helps Subtype Hepatocellular Adenomas.Radiology. 2016 Apr;279(1):118-27. doi: 10.1148/radiol.2015142449. Epub 2015 Oct 27. Radiology. 2016. PMID: 26505921
-
New MRI features improve subtype classification of hepatocellular adenoma.Eur Radiol. 2019 May;29(5):2436-2447. doi: 10.1007/s00330-018-5784-5. Epub 2018 Dec 6. Eur Radiol. 2019. PMID: 30523457
-
Hepatocellular Adenomas: Molecular Basis and Multimodality Imaging Update.Radiographics. 2023 Mar;43(3):e220134. doi: 10.1148/rg.220134. Radiographics. 2023. PMID: 36821508 Review.
-
Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.Gastroenterology. 2017 Mar;152(4):880-894.e6. doi: 10.1053/j.gastro.2016.11.042. Epub 2016 Dec 7. Gastroenterology. 2017. PMID: 27939373
-
Hepatocellular adenoma update: diagnosis, molecular classification, and clinical course.Br J Radiol. 2024 Nov 1;97(1163):1740-1754. doi: 10.1093/bjr/tqae180. Br J Radiol. 2024. PMID: 39235933 Free PMC article. Review.
Cited by
-
18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine.PLoS One. 2017 Jul 6;12(7):e0180349. doi: 10.1371/journal.pone.0180349. eCollection 2017. PLoS One. 2017. PMID: 28683109 Free PMC article.
-
A Scoping Review of the Classification, Diagnosis, and Management of Hepatic Adenomas.J Gastrointest Surg. 2022 Apr;26(4):965-978. doi: 10.1007/s11605-022-05246-8. Epub 2022 Jan 26. J Gastrointest Surg. 2022. PMID: 35083725
-
A rare case of MRI of myxoid hepatocellular adenoma with gadoxetic acid uptake.BJR Case Rep. 2023 Oct 18;9(6):20230033. doi: 10.1259/bjrcr.20230033. eCollection 2023 Nov. BJR Case Rep. 2023. PMID: 37928703 Free PMC article.
-
Hepatocellular adenoma: when and how to treat? Update of current evidence.Therap Adv Gastroenterol. 2016 Nov;9(6):898-912. doi: 10.1177/1756283X16663882. Epub 2016 Sep 28. Therap Adv Gastroenterol. 2016. PMID: 27803743 Free PMC article. Review.
-
[Radiological diagnostic workup of liver tumors].Internist (Berl). 2020 Feb;61(2):123-130. doi: 10.1007/s00108-019-00724-9. Internist (Berl). 2020. PMID: 31919534 Review. German.
References
-
- La Vecchia C, Tavani A. Female hormones and benign liver tumours. Digestive and Liver Disease. 2006;38(8):535–536. - PubMed
-
- Prentice RL. Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancers. Preventive Medicine. 1991;20(1):38–46. - PubMed
-
- Labrune P, Trioche P, Duvaltier I, Chevalier P, Odièvre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. Journal of Pediatric Gastroenterology and Nutrition. 1997;24(3):276–279. - PubMed
-
- Giannitrapani L, Soresi M, La Spada E, Cervello M, D’Alessandro N, Montalto G. Sex hormones and risk of liver tumor. Annals of the New York Academy of Sciences. 2006;1089:228–236. - PubMed
-
- Cappell MS. Hepatic disorders severely affected by pregnancy: medical and obstetric management. Medical Clinics of North America. 2008;92(4):739–760. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials